- Rising Prevalence of Chronic Diseases and Growing Number of Trauma and Injury Cases.
- Increasing Demand for Source Plasma From Biopharmaceutical Companies.
- Rising Demand for Blood Components and Growing Concerns Regarding Blood Safety.
- Increase in the Number of Complex Surgical Procedures.
- Favorable Reimbursement for Apheresis Procedures.
Recent Developments in the Global Apheresis Market:
# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.
# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.
# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (CHINA). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.
# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.
What the Market Looks Like?
The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.
The key players in the global apheresis market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), and Nikkiso Co., Ltd. (Japan).
Download PDF Brochure @ Apheresis Market
Terumo BCT, Inc. (US) was the leading player in the apheresis market and accounted for the largest share in 2018. The company is known for its diversified product offerings in the field of apheresis. Terumo’s products include the Spectra Optia, COBE Spectra, and Trima Accel, and these are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for donor & therapeutic apheresis purposes. The company has a significant global footprint owing to its strong sales and distribution network.
Fresenius SE & Co. KGaA (Germany) is a global player in the apheresis market, with wide geographic coverage. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. The company offers apheresis systems and related disposables for both donor & therapeutic apheresis through its Fresenius Kabi and Fresenius Medical Care business segments. The company strengthens its business operations by expanding its presence in emerging markets.
Haemonetics Corporation (US) is a key competitor in the apheresis market for both the collection of cells and therapeutic apheresis. The company has a strong product profile in automated blood component collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia, which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is generated from the US market. Haemonetics also focuses on high-growth emerging countries in order to increase its share in the apheresis market.
North America accounted for the largest market share in 2018
North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.
Request Sample Pages@ Apheresis Market
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.